Betta Pharmaceuticals's Four Drugs Placed on China's Insurance Drug List

Betta Pharmaceuticals (300558.SZ): Ensartinib Hydrochloride Capsules' Marketing Authorization Application Accepted by EMA

Betta Pharmaceuticals (300558.SZ): Drug Registration Application for Ensartinib Hydrochloride Capsules as Postoperative Adjuvant Therapy Accepted

Betta Pharmaceuticals' Third Attempt at Hong Kong IPO: Cash Crunch, Product Gap, and R&D Cuts – Can the "Four-Pronged Strategy" Save the Day?

Betta Pharmaceuticals: BPI-572270 is a molecular glue inhibitor, currently advancing IND submission preparations

Betta Pharmaceuticals Gets Distribution Rights for Hemophilia Drug

A-Share Innovative Drug Concept Stocks Decline, Betta Pharmaceuticals Falls Over 10%

Betta Pharmaceuticals Says Co Has Submitted Listing Apllication to Hong Kong Stock Exchange

BRIEF-Betta Pharmaceuticals Submits Listing Application To Hong Kong Stock Exchange

IPO News | Betta Pharmaceuticals Co.,Ltd. (300558.SZ) Files Application with Hong Kong Stock Exchange, Successfully Transforms into "Platform-Type Pharmaceutical Enterprise"

Betta Pharmaceuticals, "China's First Innovative Drug Stock," Makes Third Attempt at Hong Kong IPO Amid Profit Struggles and 180 Million Yuan Debt

Betta Pharmaceuticals Seeks Third Hong Kong IPO with 500 Million Yuan in Cash

Betta Pharmaceuticals Gets Board Approval for Hong Kong Listing Plan; Shares Down 4%

Betta Pharmaceuticals Says Co Plans to Seek Hong Kong Listing

BRIEF-Betta Pharmaceuticals Plans To Seek Hong Kong Listing

Betta Pharmaceuticals Co.,Ltd., the "First Innovative Drug Stock," Sees Profit Growth Hit the Brakes

Betta Pharmaceuticals' Attributable Profit Slides 38% in H1

Betta Pharmaceuticals Co.,Ltd. (300558.SZ) Reports First-Half Results with Net Profit of 140 Million Yuan, Down 37.53%

C4 Therapeutics Inc. Releases Presentation on Targeted Protein Degradation Advancements and Future Development Plans

Beta Pharma (300558.SZ) Reports Partner He Yuan Biotech's Novel Drug Ofumin Gains Market Approval